{"id":"didanosine-ddi-drug","safety":{"commonSideEffects":[{"rate":"1-2","effect":"Pancreatitis"},{"rate":"15-20","effect":"Peripheral neuropathy"},{"rate":"15-20","effect":"Diarrhea"},{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"rare","effect":"Lactic acidosis"},{"rate":"1-5","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1460","moleculeType":"Small molecule","molecularWeight":"236.23"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Didanosine is a purine nucleoside analog that is phosphorylated intracellularly to its active form, dideoxyadenosine triphosphate (ddATP). This active metabolite competes with natural deoxyadenosine triphosphate for incorporation into the growing DNA chain during reverse transcription, causing chain termination and inhibiting HIV replication. It was one of the early antiretroviral agents used in HIV treatment.","oneSentence":"Didanosine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating within host cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:23.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT05633147","phase":"PHASE1","title":"Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam","status":"COMPLETED","sponsor":"Cinclus Pharma Holding AB","startDate":"2022-11-27","conditions":"Safety Issues, Pharmacokinetics, Drug Interaction","enrollment":35},{"nctId":"NCT01605084","phase":"PHASE3","title":"Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-30","conditions":"HIV","enrollment":""},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT00109590","phase":"PHASE2","title":"Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":175},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00016718","phase":"PHASE1, PHASE2","title":"Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-08","conditions":"HIV Infections","enrollment":43},{"nctId":"NCT00000710","phase":"PHASE1","title":"A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":42},{"nctId":"NCT00001045","phase":"PHASE2","title":"Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00000891","phase":"PHASE2","title":"Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT00001068","phase":"PHASE2","title":"A Study of Disease Progression and Anti-HIV Treatments","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":210},{"nctId":"NCT00000810","phase":"PHASE1","title":"Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00000831","phase":"PHASE2","title":"Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":280},{"nctId":"NCT00000851","phase":"PHASE2","title":"Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":198},{"nctId":"NCT00000753","phase":"PHASE1","title":"A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00001029","phase":"PHASE2","title":"A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":654},{"nctId":"NCT00001063","phase":"PHASE2","title":"The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00000838","phase":"PHASE2","title":"Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":256},{"nctId":"NCT00001022","phase":"PHASE3","title":"A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1200},{"nctId":"NCT00000781","phase":"PHASE2","title":"A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1292},{"nctId":"NCT00000742","phase":"PHASE1","title":"A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT00000969","phase":"NA","title":"A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":400},{"nctId":"NCT00000803","phase":"PHASE2","title":"A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":471},{"nctId":"NCT00000770","phase":"PHASE2","title":"A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":400},{"nctId":"NCT00000657","phase":"PHASE2","title":"Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"AIDS Dementia Complex, HIV Infections","enrollment":80},{"nctId":"NCT00000656","phase":"PHASE1","title":"A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":116},{"nctId":"NCT00000637","phase":"PHASE3","title":"A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":819},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00000625","phase":"PHASE2","title":"A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":2100},{"nctId":"NCT00001024","phase":"NA","title":"The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT00001114","phase":"PHASE2","title":"The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":90},{"nctId":"NCT00007202","phase":"PHASE2","title":"Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00001057","phase":"PHASE2","title":"The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":105},{"nctId":"NCT00051090","phase":"NA","title":"Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B","enrollment":""},{"nctId":"NCT00001025","phase":"PHASE2","title":"Evaluation of Patients Who Have Not Had Success With Zidovudine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00001108","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00001048","phase":"PHASE2","title":"Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Leukoencephalopathy, Progressive Multifocal","enrollment":90},{"nctId":"NCT00008866","phase":"PHASE2","title":"Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00001074","phase":"PHASE1","title":"The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":140},{"nctId":"NCT00006339","phase":"PHASE2","title":"Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00001087","phase":"PHASE2","title":"The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00001049","phase":"PHASE1","title":"A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":180},{"nctId":"NCT00000822","phase":"PHASE1","title":"A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":46},{"nctId":"NCT00000839","phase":"PHASE1","title":"A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Pregnancy","enrollment":12},{"nctId":"NCT00000963","phase":"PHASE2","title":"A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00000954","phase":"PHASE1","title":"A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":72},{"nctId":"NCT00000916","phase":"PHASE2","title":"A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":399},{"nctId":"NCT00000924","phase":"PHASE2","title":"A Study to Compare Two Different Anti-HIV Drug Regimens","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00000902","phase":"PHASE1","title":"A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":217},{"nctId":"NCT00000939","phase":"PHASE2","title":"A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT00000865","phase":"PHASE1","title":"The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT00000772","phase":"PHASE1","title":"A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT00000885","phase":"PHASE2","title":"Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":440},{"nctId":"NCT00000823","phase":"PHASE2","title":"A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":85},{"nctId":"NCT00000833","phase":"PHASE1","title":"A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT00000814","phase":"PHASE1","title":"A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":390},{"nctId":"NCT00084136","phase":"PHASE4","title":"Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-05","conditions":"HIV Infections","enrollment":1571},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT00928187","phase":"PHASE3","title":"Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2009-11","conditions":"HIV, HIV Infections","enrollment":454},{"nctId":"NCT01440569","phase":"PHASE3","title":"Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-09","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":314},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01363011","phase":"PHASE3","title":"Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-05","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":106},{"nctId":"NCT00338390","phase":"PHASE3","title":"Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC","status":"COMPLETED","sponsor":"Hospital de Granollers","startDate":"2005-04","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT02251873","phase":"PHASE1","title":"Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-09","conditions":"Healthy","enrollment":50},{"nctId":"NCT00364793","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-02","conditions":"HIV Infections","enrollment":56},{"nctId":"NCT00000922","phase":"NA","title":"A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1710},{"nctId":"NCT00002905","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Centro di Riferimento Oncologico - Aviano","startDate":"1995-06","conditions":"Lymphoma","enrollment":20},{"nctId":"NCT00006154","phase":"PHASE3","title":"A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":165},{"nctId":"NCT00014937","phase":"NA","title":"Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT00342355","phase":"PHASE4","title":"Antiretroviral Therapy for Advanced HIV Disease in South Africa","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2004-01","conditions":"HIV","enrollment":1771},{"nctId":"NCT00000652","phase":"PHASE1","title":"A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"","conditions":"HIV Infections","enrollment":85},{"nctId":"NCT00703586","phase":"PHASE1","title":"Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2007-09","conditions":"HIV Infections","enrollment":8},{"nctId":"NCT00197613","phase":"PHASE3","title":"The Adult Antiretroviral Treatment and Resistance Study (Tshepo)","status":"COMPLETED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2002-12","conditions":"AIDS, HIV Infection","enrollment":650},{"nctId":"NCT00000919","phase":"NA","title":"A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":900},{"nctId":"NCT00000870","phase":"PHASE2","title":"A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00000918","phase":"PHASE2","title":"A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00000923","phase":"NA","title":"Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":110},{"nctId":"NCT00013520","phase":"PHASE3","title":"Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1125},{"nctId":"NCT00034086","phase":"NA","title":"Study of Anti-HIV Therapy Intensification","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT00001035","phase":"PHASE1","title":"The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":10},{"nctId":"NCT00192660","phase":"PHASE4","title":"HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2003-02","conditions":"HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease","enrollment":80},{"nctId":"NCT00142337","phase":"PHASE2","title":"One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2004-12","conditions":"HIV Infections","enrollment":244},{"nctId":"NCT00122538","phase":"PHASE2","title":"Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2006-02","conditions":"HIV Infections, AIDS","enrollment":52},{"nctId":"NCT00002035","phase":"NA","title":"Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00002280","phase":"NA","title":"A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00002240","phase":"PHASE2","title":"Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1999-03","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00002429","phase":"PHASE3","title":"Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1999-07","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT00002224","phase":"PHASE3","title":"Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1999-03","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00002411","phase":"NA","title":"A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1998-03","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00002207","phase":"NA","title":"A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-02","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00116415","phase":"NA","title":"DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-03","conditions":"HIV Infections, AIDS","enrollment":65},{"nctId":"NCT00002177","phase":"NA","title":"A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1997-05","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00002360","phase":"PHASE1","title":"A Study Comparing Two Forms of Didanosine in HIV-infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1999-03","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00002176","phase":"NA","title":"A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1997-05","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00000982","phase":"PHASE2","title":"A Study of Azidothymidine in HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Encephalopathies, HIV Infections","enrollment":75},{"nctId":"NCT00000672","phase":"PHASE2","title":"An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":660},{"nctId":"NCT00000979","phase":"PHASE2","title":"Comparison of ddI Versus Zidovudine in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"didanosine, ddI (drug)","genericName":"didanosine, ddI (drug)","companyName":"French National Agency for Research on AIDS and Viral Hepatitis","companyId":"french-national-agency-for-research-on-aids-and-viral-hepatitis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Didanosine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating within host cells. Used for HIV-1 infection (as part of combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}